Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Humongous Health-Care Stocks This Week: Dendreon Corporation (DNDN), Neurocrine Biosciences, Inc. (NBIX)

Page 1 of 2

As millions of Americans brace themselves for a massive blizzard, a handful of health-care stocks have been heating up the charts over the past few days. Here they are — three of the most humongous performers for this week.

Overcoming peer pressure
Strong earnings and great guidance will do the trick nearly every time. Both certainly helped shares of USANA Health Sciences, Inc. (NYSE:USNA) this week. The network marketer of nutritional supplements and weight-management products saw shares jump 24% over the past few days.

USANA reported earnings for last quarter of $1.27 per share, handily beating analyst estimates of $1.21 per share. The company beat on revenue also, posting sales of $168.5 million compared with the $165.6 million total that analysts expected. With 2013 guidance also well above analysts’ views, a huge stock surge isn’t surprising.

Dendreon Corporation (NASDAQ:DNDN)However, USANA’s success this week came in spite of peer pressure of sorts. The ongoing controversy stemming from attacks by hedge fund manager Bill Ackman on Herbalife Ltd. (NYSE:HLF) have hurt several multilevel marketing companies. With this week’s nice gains, USANA has climbed back above where the stock was before Ackman’s public allegations that Herbalife is a pyramid scheme.

Surprise, surprise
Neurocrine Biosciences, Inc.
(NASDAQ:NBIX) is another company in the health-care sector with good earnings news. Shares jumped 21% this week following Neurocrine’s announcement of fourth-quarter results.

Analysts were expecting the small biotech to report a loss of $0.08 per share. Neurocrine surprised them with positive earnings of $0.14 per share. Revenue of $21.9 million was nearly twice the level from fourth quarter of 2011.

The surprise bonus stemmed from the company’s collaboration with AbbVie Inc (NYSE:ABBV) on elagolix. The drug, which targets treatment of pain associated with endometriosis, is in late-stage clinical studies. Elagolix is also part of a phase 2 study in helping treat uterine fibroids.

Revenge of Provenge?
After shares fell off a cliff back in August 2011 because of disappointing sales of prostate cancer drug Provenge, Dendreon Corporation (NASDAQ:DNDN) has been on a tear lately. Shares increased more than 16% this week.

Dendreon’s big move this week is likely to stem from several factors. Probably the most important is anticipation that Provenge could gain a positive recommendation from a key European committee as early as the first quarter of this year. Another related catalyst is that analysts are more bullish on the stock these days. Sanford C. Bernstein analyst Geoffrey Porges thinks urologists will use Provenge at a much higher rate in 2013. Cantor Fitzgerald recently raised its price target for Dendreon to $7 per share, a level the stock now hovers near.

Dendreon fueled this positive buzz last month, when it provided earnings guidance higher than what analysts were expecting. While it’s been a long road and there are probably plenty of potholes and detours ahead, shareholders just might yet see Provenge get some measure of revenge with naysayers.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!